Works matching AU Catalano, V.

Results: 40
    1
    2
    3
    4
    5
    6
    7
    8

    A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.

    Published in:
    British Journal of Cancer, 2008, v. 98, n. 1, p. 71, doi. 10.1038/sj.bjc.6604121
    By:
    • Cascinu, S.;
    • Berardi, R.;
    • Salvagni, S.;
    • Beretta, G. D.;
    • Catalano, V.;
    • Pucci, F.;
    • Sobrero, A.;
    • Tagliaferri, P.;
    • Labianca, R.;
    • Scartozzi, M.;
    • Crocicchio, F.;
    • Mari, E.;
    • Ardizzoni, A.
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16

    The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

    Published in:
    British Journal of Haematology, 2013, v. 161, n. 4, p. 508, doi. 10.1111/bjh.12274
    By:
    • Verstovsek, Srdan;
    • Mesa, Ruben A.;
    • Gotlib, Jason;
    • Levy, Richard S.;
    • Gupta, Vikas;
    • DiPersio, John F.;
    • Catalano, John V.;
    • Deininger, Michael;
    • Miller, Carole;
    • Silver, Richard T.;
    • Talpaz, Moshe;
    • Winton, Elliott F.;
    • Harvey, Jimmie H.;
    • Arcasoy, Murat O.;
    • Hexner, Elizabeth;
    • Lyons, Roger M.;
    • Paquette, Ronald;
    • Raza, Azra;
    • Vaddi, Kris;
    • Erickson‐Viitanen, Susan
    Publication type:
    Article
    17
    18
    19
    20
    21
    22

    Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.

    Published in:
    Pharmacogenomics Journal, 2010, v. 10, n. 5, p. 458, doi. 10.1038/tpj.2010.9
    By:
    • Graziano, F.;
    • Canestrari, E.;
    • Loupakis, F.;
    • Ruzzo, A.;
    • Galluccio, N.;
    • Santini, D.;
    • Rocchi, M.;
    • Vincenzi, B.;
    • Salvatore, L.;
    • Cremolini, C.;
    • Spoto, C.;
    • Catalano, V.;
    • D'Emidio, S.;
    • Giordani, P.;
    • Tonini, G.;
    • Falcone, A.;
    • Magnani, M.
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29

    High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

    Published in:
    British Journal of Cancer, 2004, v. 90, n. 8, p. 1521, doi. 10.1038/sj.bjc.6601752
    By:
    • Cascinu, S.;
    • Scartozzi, M.;
    • Labianca, R.;
    • Catalano, V.;
    • Silva, R. R.;
    • Barni, S.;
    • Zaniboni, A.;
    • Angelo, A. D.;
    • Salvagni, S.;
    • Martignoni, G.;
    • Berardi, R.;
    • Graziano, F.;
    • Beretta, G. D.;
    • Franciosi, V.
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37

    Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

    Published in:
    Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0417-z
    By:
    • Verstovsek, Srdan;
    • Mesa, Ruben A.;
    • Gotlib, Jason;
    • Gupta, Vikas;
    • DiPersio, John F.;
    • Catalano, John V.;
    • Deininger, Michael W. N.;
    • Miller, Carole B.;
    • Silver, Richard T.;
    • Talpaz, Moshe;
    • Winton, Elliott F.;
    • Harvey Jr., Jimmie H.;
    • Arcasoy, Murat O.;
    • Hexner, Elizabeth O.;
    • Lyons, Roger M.;
    • Paquette, Ronald;
    • Raza, Azra;
    • Jones, Mark;
    • Kornacki, Deanna;
    • Kang Sun
    Publication type:
    Article
    38
    39
    40